Konstantinos Efthymiopoulos

# Only put off until tomorrow what you are willing to die having left undone. ## The HIFI Study: New Breakthrough in Prostate Cancer Treatment Prostate cancer has long been a concern for many individuals and their families. However, a recent study, known as the HIFI Study, has shed new light on the treatment options available for localized prostate cancer. EDAP TMS SA, a leading healthcare company, announced the publication of the HIFI Study results in the prestigious journal European Urology. This groundbreaking study highlights the efficacy of the Focal One Robotic High Intensity Focused Ultrasound \(HIFU\) treatment. The HIFI Study provides compelling evidence that HIFU offers comparable effectiveness and improved functional outcomes when compared to radical prostatectomy, a traditional surgical procedure for prostate cancer. This innovative robotic treatment proves to be a game-changer, offering patients a less invasive option with promising results. As an experienced Investment Advisor, I encourage you to take action and explore the potential investment opportunities in companies like EDAP TMS SA that are at the forefront of cutting-edge healthcare technologies. By investing in your health savings account \(HSA\), you not only secure financial growth but also contribute to the advancement of groundbreaking medical treatments. Don't miss out on the chance to be part of this transformative journey in healthcare and make a positive impact on your own well-being, your family, and the world. Empower yourself with knowledge, invest wisely, and seize the opportunities that arise. #hsa #investing #healthcare #health #family #wellness 💪💰🏥

1

#WhySwitzerland for biotech & pharma? 💡 Anne Marie de Jonge-Schuermans, Board Member of the 🇨🇭 Swiss Biotech Association and Global Head of Biologics & Injectables Operations at Sandoz, discusses the Swiss biopharma ecosystem and the business and career opportunities with Medicine Maker. 🚀 Read about it in this article: https://loom.ly/D6U5z3k The Medicine Maker, Swiss Biotech Association, Sandoz

12

📈 GRIP-Pharma brings together the dynamic community of French-speaking pharmas and biotechs in Switzerland. Proud partners of the Swiss Biotech Association, we're thrilled to share the insights from the latest SWISS BIOTECH REPORT 2024. Dive into the report to uncover the newest trends and statistics shaping our industry! https://lnkd.in/gfkz7FH #GRIPPharma #SwissBiotech #Pharma #Biotech #IndustryInsights.

5

👋 Hello #3Rs experts and enthusiasts! Meet us tomorrow, June 13, at the Swiss 3Rs Day! Organized by Swiss 3RCC, this year's topic is 3Rs in Oncology and we couldn't be more excited to engage with leading experts, develop potential collaborations, and discover the new research standards in #oncology. 📍Say hi to our team at the Nagi Bioscience booth! We want to hear more about your research, your needs, and explore how our Organism-on-Chip technology can help you to achieve your goals. 🌟 Curious about how our technology bridges the gap between in vitro and in vivo testing with ethical full organism data? Download here the poster presented last month at The 3Rs Länd Conference 👉🏼 https://lnkd.in/exBb-pCa See you tomorrow at AGORA Cancer Research Center 👋🏼 #inwormwetrust #safetytesting #efficacy #OoO #microfluidics #labautomation #labtechnology #drugdiscovery #toxicology #NAMs #AI

11

1 Kommentar

🎬 Learn more about BioAlps - Life Sciences Cluster 🇨🇭 in the latest instalment of Greater Geneva Bern area (GGBa) "WHAT IS" series!

2

The Rare Disease Action Forum brings together voices from actors in the field of rare diseases representing the industry, healthcare professionals, patient and research organizations to improve the lives of patients with rare diseases in Switzerland. Our objectives include: 👉 Raising awareness about rare diseases in Switzerland and foster dialogue about patients’ needs 👉 Assessing and adapting the Swiss environment to the needs of patients with rare diseases 👉 Adapting the standards to enable equal and fair treatment for patients with rare diseases Join our multi-stakeholder association or discover more RDAF objectives: https://bit.ly/3nKB4B1 #rarediseases #Switzerland

4

Yesterday, Marc-Olivier Mignon, Chief Commercial Officer of CELLforCURE by Seqens, was delighted to attend the Pharma Days in Geneva, engaging in insightful discussions about the future of pharma manufacturing and the ramp-up of CDMOs in the Cell & Gene field.   Panel Highlight: "𝘙𝘦𝘭𝘰𝘤𝘢𝘵𝘪𝘯𝘨 𝘗𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭 𝘗𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘰𝘯 𝘵𝘰 𝘌𝘶𝘳𝘰𝘱𝘦”   Marc-Olivier, along with other industry leaders, shared perspectives on this critical topic. Here are his key takeaways:   Filling the API manufacturing gap is crucial to ensure European sovereignty in the pharmaceutical sector. For successful relocation, we need to: ✔️ Invest in education to cultivate the right skills and people, ✔️ Showcase political willingness to tackle unfair competition, ✔️ Provide incentives to support local industrial investments and carbon-free ambitions. Strengthening and protecting our existing innovative manufacturing networks is essential to keep them localized, fostering collaboration and growth. At CELLforCURE by Seqens, we're committed to shaping the future of therapies and driving impactful changes in the industry. Here's to more such enriching experiences and collaborations!   #PharmaDaysGeneva #CellforCurebySeqens #PharmaManufacturing #CDMO #EuropeanSovereignty #Ourscienceforyourfuture 

110

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy. We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

4

Asceneuron SA, a clinical-stage biotech company based in Lausanne, Switzerland, has successfully raised $100 million in Series C funding to advance its innovative approach to treating neurodegenerative diseases. The company, which focuses on developing small molecules targeting tau protein aggregation, will use the funds to progress its lead asset ASN51 into Phase 2 clinical trials for Alzheimer's disease treatment. The financing round was led by Novo Holdings, with new investments from EQT Life Sciences – LSP Dementia Fund, OrbiMed, and SR One, alongside participation from existing investors, including M Ventures, Sofinnova Partners, GSK Equities Investments Limited, and Johnson & Johnson Innovation – JJDC, Inc. This substantial investment underscores the potential of Asceneuron's OGA inhibitor pipeline and its leadership in tauopathies, as noted by the company's CEO, Barbara Angehrn Pavik. https://lnkd.in/gkg9ZCJx

1

Swiss Biotech's 2024 Turnaround: Breaking Revenue Records Despite Funding Hurdles While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience. Key takeaways from the report include... 💹 Record Revenues: Despite a global funding downturn, the Swiss biotech sector showcased resilience with a revenue spike to CHF 7.3 billion in 2023, a significant leap from the previous year. 💸 Strategic Capital Increases: Investment surged over 50%, with CHF 2 billion raised in 2023, demonstrating a robust appetite for innovative Swiss biotech ventures. 🤝 Dynamic M&A Activity: The industry remained vibrant with key mergers and acquisitions, highlighting ongoing growth and expansion opportunities within the sector. Get the full picture in Amanda Saionz's latest piece at https://lnkd.in/dnJ6DkXh

4

🆕🗞️For the eleventh time in succession, Swissmedic, the Swiss authority for the authorisation and monitoring of therapeutic products, and the Swiss pharmaceutical industry associations (ASSGP, Intergenerika, Interpharma, scienceindustries and vips) have conducted a benchmarking study analysing the times required to authorise human medicinal products in Switzerland and comparing them with the equivalent times for the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). 📊The results provide a factual basis for the ongoing dialogue between Swissmedic and the pharmaceutical industry. They help identify and implement improvements in the authorisation processes for human medicinal products.📈 https://bit.ly/4deogaA #Pharma #Healthcare #RegulatoryAffairs #Benchmarking #Swissmedic #EMA #FDA #Innovation #authorisationtimes #humanmedicines

2

𝗧𝗮𝗰𝗮𝗹𝘆𝘅 𝗘𝘅𝘁𝗲𝗻𝗱𝘀 𝗦𝗲𝗲𝗱 𝗥𝗼𝘂𝗻𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿 €𝟭𝟰 𝗠 𝘁𝗼 𝗔𝗱𝘃𝗮𝗻𝗰𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗶𝘁𝘀 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗧𝗔𝗖𝗔𝘀: Tacalyx GmbH, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) #cancer #therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan Castiglia, Partner at Thuja Capital, will join the Board of Directors. Thuja joins the existing investors Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, HTGF | High-Tech Gründerfonds (HTGF), coparion, IdInvest/Eurazeo, Creathor Ventures and the Max Planck Society (MPG). Tacalyx is a pioneer in the development of novel antibody-based therapeutics targeting TACAs, glycan structures that are often found on cancer cells but are absent from differentiated tissues under normal physiologic conditions. Thus, anti-TACA antibodies allow for specific targeting of cancer cells and can be further developed into various treatment modalities, including antibody-drug conjugates (ADCs) or T cell engagers (TCEs). With its unique expertise in glycan biology and manipulation, Tacalyx has established a pipeline of several first-in-class assets targeting different TACAs across multiple solid tumor indications. With the additional funds, Tacalyx will develop two of its novel antibodies into late preclinical stage as well as advance several earlier stage programs. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eYmtiUGi Evan Castiglia, Peter Sondermann

4

The Start of a New Era of Differentiating Viral and Bacterial Infections: A Machine Learning Model Based on Routine Blood Test Values 🦠💊   Our team at Smart Blood Analytics Swiss SA, alongside a multidisciplinary medical team, unveils a new approach in the fight against antibiotic resistance. Our latest study, "Differentiating Viral and Bacterial Infections: A Machine Learning Model Based on Routine Blood Test Values," just published in Heliyon, introduces the VIRUS vs. BACTERIA AI model. This innovative tool leverages 16 routine blood test results, CRP levels, biological sex, and age to accurately distinguish between viral and bacterial infections with an impressive 82.2% accuracy rate. Read the whole article at: https://lnkd.in/guzJ37ks #VIRUSvsBACTERIA #AImodel #innovation

19

🎯 [ Swiss Biotech Day ] 📅 April 22 & 23 📍 Congress Center Basel 🌟 Thank you to everyone Léa Petitjean had the opportunity to engage with at the Swiss Biotech Day! ⏲ For those who haven’t met our team and discussed how CREAPHARM can meet your supply chain needs for #vaccines, #immunotherapies, or #ATMPs, don't worry! 👉 Contact us to schedule a meeting or to learn more about our tailored solutions. #coldchain #ultracold #supplychain #clinicalsupply

45

#ESMO24 | The EU is facing a difficult situation, is it doing better in the field of oncology? Is there a European oncology represented by ESMO? Can a European oncology policy be also a resource for hashtag #globaloncology? The opinion of Andres Cervantes, ESMO President 👉 https://lnkd.in/gbr4x-vG ESMO - European Society for Medical Oncology

4

“We must secure a sustainable future where innovation and patient care thrive together” David Traub recently outlined this key priority and further topics such as access to innovative treatments, digitization in our healthcare system and more in an interview with Pharma Boardroom. Read more below

23

🔬Switzerland has a long-standing reputation for innovation in pharmaceuticals and biotechnology. A recent article by Labiotech.eu highlights 18 outstanding Swiss biotech companies in areas like gene and cell therapy, cancer treatments and therapies addressing conditions that come with age. We're thrilled to see two of our Switzerland Innovation Park Basel Area - Main Campus residents featured among them: ✨Alentis Therapeutics is a clinical-stage biotechnology company developing innovative therapies targeting claudin-1 positive tumors - a significant unmet medical need. ✨Engimmune Therapeutics is a preclinical company developing next-generation T cell therapies for cancer patients. 👉Read the whole list over here:  https://lnkd.in/gnPbAhQ These are just two examples of the groundbreaking biotech companies that call Switzerland Innovation Park Basel Area their home. Our modern facilities and supportive community provide the perfect platform for companies to develop and thrive. 💡Are you a biotech entrepreneur looking to embark on your own success story? Reach out to us and discover our available workspaces. Roberto Iacone | Rodrigo Vazquez-Lombardi | Lars Nieba | Karin Crisanto | Basel Area Business & Innovation #innovation #biotech #healthcare #pharma #startups

63

2 Kommentare

We are happy to share with you a short video describing clearly and quickly what the SG-OCRA Technology is all about and how 1 minute of testing can help counter the often underestimated problem of Oral Cancer. OPEN VIDEO > https://lc.cx/rGqvfo #studiumgenetics #oralcarcinoma #oralcancer #headandneckcancer #oralcancerday

4

The Enterome Team will attend the ESMO IO Meeting 2024 from December 11 to 13, 2024, in Geneva. We’re excited to share new clinical data findings from the Phase 1/2 ‘AUDREY’ trial of EO4010 in Colorectal Cancer, one poster presentation will feature promising efficacy data from Cohort 2 and 3 of the AUDREY study. If you're attending ESMO - European Society for Medical Oncology Immuno-Oncology (I/O) Meeting 2024, join us to learn more: 📅 Poster presentation details:   Abstract #457 - Title: EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC) - Presenting Author: Dr. Romain Cohen, Department of medical oncology, Saint-Antoine hospital, AP-HP, Assistance Publique - Hôpitaux de Paris, and Assistant Professor of Oncology at Sorbonne Université, Paris - Poster Session: presentation time December 12, 12:00 PM-13:00 PM CET A special thank you to our presenting authors, the investigators in this international, multicenter study, and the patients and their families who make this research possible. #ESMOIO2024 #Enterome #Oncology #Immunotherapy #ClinicalTrials #CancerResearch #Colorectalcancer #CancerInnovation

20